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A 27-year-old woman was admitted for intractable right-sided neck, ear, and jaw pain with gradual development of tinnitus and
hearing loss. A cerebral MRI showed meningo-dural enhancement, and additional diagnostic workup revealed a right pulmonary
inﬁltrateandpositivePR-3ANCA.Biopsiesfromnasalmucosaandlungshowedchronicinﬂammationwithgranulomaformation.
Based on these ﬁndings the patient was diagnosed with Wegener’s granulomatosis with pachymeningitis. There was no clinical
response to oral Prednisolone and Cyclophosphamide, but complete clinical and imaging remission was achieved by adding
Rituximab.
1.Introduction
Pachymeningitis is a rare feature of Wegener’s granulomato-
sis (WG) and an uncommon initial manifestation of the
disease [1]. We demonstrate that pachymeningeal lesions
refractory to conventional therapy can resolve completely
by the addition of Rituximab (RTX) to standard remedies.
This case also illustrates that besides global headache, WG-
related pachymeningitis may occasionally manifest itself by
lateralized pain and cranial nerve involvement [2–5].
2.CaseReport
In 2004, a 27-year-old Caucasian female was admitted for
persistent right-sided ear, jaw, and neck pain, with recent
advent of tinnitus, hearing loss, and nasal sores. A CT-
scan showed mucosal thickening of the maxillary sinuses
without bony erosions. A biopsy from nasal mucosa showed
vasculitis and granuloma formation. Chest CT showed an
apical inﬁltrate in the right lung and no mediastinal lym-
phadenopathy. A transthoracic lung biopsy revealed necrotic
tissue and chronic inﬂammation with granuloma formation.
Bronchoalveolarlavage(BAL)ﬂuidwasnegative forbacterial
growth, mycobacterial PCR, and malignant cells. A PPD skin
test wasnegative. However, thepatienttested positiveforPR-
3 ANCA (49U/mL, <10). Blood cell counts were normal,
CRPbelow15mg/L,creatinineclearance,andurinalysiswere
normal. Based on these ﬁndings, the patient was diagnosed
with Wegener’s granulomatosis [6].
Cerebral magnetic resonance imaging (MRI) with ga-
dolinium showed infratentorial, meningeal thickening along
the right cerebellar tentorium, the cerebellopontine angle
ascending into the right foramen jugulare. Besides, a throm-
bus extending from the right sinus transversus to bulbus
venae jugularis was diagnosed. No nodular enhancement or
infarcts were noted. Based onthese ﬁndings, Wegenerrelated
pachymeningitis was suspected although not histologically
conﬁrmed.
Induction treatment included intravenous methylpred-
nisolone pulses (1gram/day for 3 days), plasma exchange on
5 consecutive days, and oral Cyclophosphamide.
Low molecular weight heparin and warfarin were added
for prophylaxis against progression of cerebral venous
thrombosis.2 ISRN Rheumatology
Table 1: Clinical characteristics and outcomes in previous cases of Wegener’s meningitis treated with Rituximab.
Reference Patient Previous
therapy
Treatment protocol Followup
(mo)
Time to
relapse
(mo)
Rituximab
cycles Outcome
Bawa et al.
2007 [7]
Female
36 years
CYC pulse
and GC
pulse
First day: Rituximab
(1g. iv.)
Methylprednisolone
(250mg iv.)
Second day:
Cyclophosphamide
(750mg iv.)Regime
repeated once 2 weeks
later.
6 No
relapse 1
Complete clinical
remission,MRI
ﬁndings
persistent.
Tamura et
al. 2007
[8]
Female
19 years
CYC pulse,
GC oral,
and MTX
Rituximab
(375mg/m2) weekly
in four weeks
Prednisolone
100mg/day gradually
tapered
12 9 2 BVAS (19→2)
Tamura et
al. 2007
[8]
Female
35 years
CYC pulse,
GC oral
and pulse,
and
MTX/CSA
Rituximab
(375mg/m2) weekly
in four weeks
Prednisolone
50mg/day gradually
tapered
5 No
relapse 1B V A S ( 1 3 →3)
Henes et
al. 2007
[9]
Male
45 years
CYC oral
and pulse,
GC oral,
and INF
Rituximab
(375mg/m2) weekly
in four weeks
Prednisolone
1mg/kg/day gradually
tapered. Leﬂunomide
20mg/day
21 18 2
Some clinical and
MRI
improvement.
Sharma et
al 2010
[10]
Female
22 years
GC oral
and pulse,
MTX, and
CYC pulse
Rituximab
(375mg/m2) weekly
in four weeks
Prednisolone
60mg/day gradually
tapered.
66 2
Clinical remission
MRI not
described
Presented
case
Female
28 years
CYC oral
and pulse,
GC oral,
MTX, and
AZA
Rituximab
(375mg/m2) weekly
in four weeks
On separate day in
each week:
Methylprednisolone
(250mg iv.)
Cyclophosphamide
(500mg/m2 iv.)
30 9 4
Complete clinical
and MRI
remission
BVAS: Birmingham vasculitis activity score modiﬁed for WG, CYC: Cyclophosphamide, GC: Glucocorticosteroids, MTX: Methotrexate, CSA: Cyclosporine
A, INF: Inﬂiximab, AZA: Azathioprine. Iv.: intravenous.
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Figure1:(a)T1Wgadolinium-enhancedMRI12.20.2006showingmeningealthickeningwithenhancementonthedorsalandlateralaspects
oftheclivus closeto thetransversesinus (arrows).(b) T1Wgadolinium-enhancedMRI06.08.2007.Themeningealthickeningonthebackof
clivus hascompletely regressed, butthe thickeningonthe rightsidenear thetransversesinus remainsvisible. (c)T1W gadolinium-enhanced
MRI 02.12.2009. Meningeal thickening and enhancement have resolved completely.
However, the Cyclophosphamide dosing target at
2mg/kgcouldnotbe achievedduetodebilitatingnausea and
liver toxicity, and she suﬀered from persistent cervicocranial
pain despite normal CRP, PR-3 ANCA seroconversion, and
partial regression of meningeal pathology by MRI.
In December 2006, the patient complained of diplopia.
A repeat MRI scan showed marked progression of the
infratentorial dura-meningeal enhancement (Figure 1(a)),
whereas partial revascularisation of the transverse sinus
was noted. Azathioprine 50mg/daily was added to the
current Prednisolone medication (50mg daily), but it hadISRN Rheumatology 3
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Figure 2: Cumulated annual Prednisolone and Cyclophosphamide
(CYC) dose (gram). Rituximab (RTX) treatment cycles are indi-
cated by arrows.
to be discontinued after 3 weeks due to intolerable nausea
and elevated liver enzymes. Due to similar drug toxicity,
Methotrexate 15mg weekly added to daily 40mg Pred-
nisolone medication was abandoned after 2 months treat-
ment. In February 2007, Rituximab was added as follows:
4 weekly Rituximab infusions (375mg/m2)c o m b i n e dw i t h
i.v.Methylprednisolone(250mg)andi.v.Cyclophosphamide
(500mg/m2) on a separate day. Already within 1 week after
the ﬁrst infusion, diplopia and neck pain had vanished. A
follow-up MRI at 6 months showed partial regression of the
meningeal pathology (Figure 1(b)), and chest CT revealed
complete regression of the lung inﬁltrate. PR-3 ANCA
remainednegative.Cyclophosphamidewasdiscontinuedand
Prednisolone gradually tapered to 5mg daily. Subsequently,
relapsing neckand earpain with concomitantepistaxis,nasal
sores or sinusitis occurring at 8–10 months intervals have
been successfully brought into remission 4 times using the
treatment protocol described above. PR-3 ANCA has been
undetectable throughout.
An MRI-scan in February 2009 showed complete regres-
sion of meningo-dural enhancement (Figure 1(c)).
3.Discussion
Global headache is the most frequent manifestation of
WG related pachymeningitis although the condition may
occasionally manifest itself with lateralized pain and cranial
nerve involvement like in the present case [2–5].
Signs and symptoms of meningeal involvement in
WG may result from diﬀerent disease processes including
vasculitis, bony destruction by invasive inﬂammatory cell
inﬁltrationorintraparenchymal granulomaformation[3,5].
Besides, the increased risk of complicating venous throm-
boembolism reported recently should be considered as
illustrated by the sinus thrombosis encountered in this case
[11].
T h er e l a t i v ec o n t r i b u t i o no ft h e s ep a t h w a y sc a n n o tb e
settled in this case, but the absence of destruction and
granulomatous lesions by MRI favours a dominant role of
vasculitis. Although conventional therapy using oral Pred-
nisolone and Cyclophosphamide was followed by regression
of the meningeal lesions seen on MRI, a parallel clinical
response was not achieved. Probably, this is due to the
submaximal dosing of these agents due to adverse eﬀects.
Based on reports on favourable responses of RTX in
refractory WG, we decided to add Rituximab to i.v. CYC
and Glucocorticoid pulses. Although the exact mechanism
behind the response to RTX in WG patients is unknown, it is
likely that targeting CD20+ B-cells, which are precursors of
ANCA-producing plasma cells, is important as evidenced by
the long-term PR-3 ANCA seroconversion observed in this
patient.
Successful treatment of Wegener’s meningitis has been
reported in the past (Table 1)[ 7–10]. This case is unique
by demonstrating that multiple RTX cycles can be admin-
istered safely and eﬀectively, resulting in long-term complete
clinical and imaging remission despite substantially reduced
immunosuppressivecomedication,glucocorticoidsinpartic-
ular (Figure 2).
The eﬀect of each single agent applied in the present
combination protocol can not be determined. However, as
shown in Figure 2, a marked reduction of the median PDN
and CYC doses was observed during RTX treatment as
compared with the pre-RTX period, thereby supporting the
notion of a speciﬁc eﬀect of RTX on WG disease pathways.
This view is further supported by the need for repeat
infusions (Figure 2).
In conclusion, this paper illustrates that WG may present
with localized meningeal involvement and that Rituximab
added to conventional agents has a steroid sparing eﬀect and
canleadtoclinicalandimagingremissioninWegener-related
pachymeningitis.
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